Latest Manufacturing News

LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.

EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.

ChemX Materials Limited has entered voluntary administration following a turbulent quarter marked by convertible note amendments, a trading suspension, and ongoing funding challenges.

Scout Security reports a significant 48% reduction in operating cash outflows for the June quarter, while holding just $78,000 in cash and advancing talks to acquire Roo Inc. The company is navigating funding challenges amid an ongoing ASX trading suspension.

Scout Security reported a significant 62% reduction in operating cash outflows for Q3 FY2025, while advancing a potential acquisition and partnership opportunities following CES. The company’s cash position remains tight, prompting ongoing capital raising efforts.

Scout Security reports a 52% jump in quarterly cash receipts and a 31% reduction in operating outflows, while advancing plans to acquire New York’s Roo Inc.

Blue Star Helium Limited reports steady progress on its Galactica helium project in Colorado, with first helium production on track for December 2025 and full ramp-up expected through 2026.

Blue Star Helium has decided not to exercise its purchase option on key Colorado helium assets after thorough evaluation, signaling a strategic pivot in its growth approach.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

Mont Royal Resources Ltd (ASX – MRZ) has lodged a prospectus to raise between A$8 million and A$10 million through a share offer priced at A$0.20 each, coinciding with a proposed merger with Commerce Resources Corp (TSXV – CCE). The combined entity aims to become a leading Quebec-focused critical minerals developer.

Renascor Resources has begun construction of its Purified Spherical Graphite demonstration facility in Adelaide, aiming to showcase an innovative HF-free purification process and disrupt China’s near-monopoly on PSG supply.